WallStreetZenWallStreetZen

NASDAQ: VTGN
Vistagen Therapeutics Inc Stock Ownership - Who owns Vistagen Therapeutics?

Insider buying vs selling

Have Vistagen Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Reid G. AdlerCHF CORP DEVEL OFF GEN COUNS2023-12-29167$1.72
$286.74Buy
Shawn SinghCHIEF EXECUTIVE OFFICER2023-12-29167$1.72
$286.74Buy
Commodore Capital LP10% Owner2023-08-07775,756$23.15
$17.96MBuy
Reid G. AdlerCHIEF LEGAL OFFICER2023-06-30167$1.59
$265.36Buy
Jerrold Duane DotsonVP CFO2023-06-30167$1.59
$265.36Buy
Shawn SinghCHIEF EXECUTIVE OFFICER2023-06-30167$1.59
$265.36Buy

1 of 1

VTGN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when VTGN insiders and whales buy or sell their stock.

VTGN Shareholders

What type of owners hold Vistagen Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Venrock Healthcare Capital Partners Ii LP76.36%20,637,286$69.13MInsider
Holding Co Cato12.25%3,310,836$11.09MInsider
Tcg Crossover Management LLC9.90%2,676,580$8.97MInstitution
Bvf Inc7.40%2,000,000$6.70MInstitution
Great Point Partners LLC6.88%1,858,735$6.23MInstitution
Stempoint Capital LP6.84%1,848,582$6.19MInstitution
Vanguard Group Inc6.64%1,793,166$6.01MInstitution
Commodore Capital LP5.83%1,575,000$5.28MInstitution
Platinum Long Term Growth Vii LLC5.77%1,558,862$5.22MInsider
Nantahala Capital Management LLC5.62%1,517,696$5.08MInstitution

1 of 3

VTGN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
VTGN38.52%61.48%Net Buying
PMVP60.81%39.19%Net Buying
ASMB3.79%96.21%Net BuyingNet Selling
COYA22.84%14.55%Net Buying
ALVR14.62%85.38%Net BuyingNet Selling

Vistagen Therapeutics Stock Ownership FAQ

Who owns Vistagen Therapeutics?

Vistagen Therapeutics (NASDAQ: VTGN) is owned by 63.98% institutional shareholders, 102.11% Vistagen Therapeutics insiders, and 0.00% retail investors. Venrock Healthcare Capital Partners Ii LP is the largest individual Vistagen Therapeutics shareholder, owning 20.64M shares representing 76.36% of the company. Venrock Healthcare Capital Partners Ii LP's Vistagen Therapeutics shares are currently valued at $66.66M.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.